Artiva Biotherapeutics, Inc. ARTV Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $19.31M+13.3% | $16.99M+27.6% | $17.63M+30.4% | $17.86M+44.8% | $17.05M+52.9% | ||
| $5.12M0.0% | $4.94M-0.2% | $5.26M+9.4% | $4.95M+28.3% | $5.12M+42.7% | ||
| $24.43M+10.2% | $21.93M+20.1% | $22.9M+24.9% | $22.81M+40.9% | $22.17M+50.4% | ||
| $24.43M+10.2% | $21.93M+20.1% | $22.9M+24.9% | $22.81M+40.9% | $22.17M+50.4% | ||
| -$24.43M-10.2% | -$21.93M-20.1% | -$22.9M-24.9% | -$22.81M-40.9% | -$22.17M-53.0% | ||
| $912K-51.1% | $1.16M-46.6% | $1.37M-25.7% | $1.56M+131% | $1.86M+187% | ||
| $914K-50.9% | $1.16M-46.6% | $1.37M+58.6% | $1.56M+194% | $1.86M+252% | ||
| -$23.52M-15.8% | -$20.77M-29.1% | -$21.53M-23.2% | -$21.25M-19.1% | -$20.31M-45.5% | ||
| -$0.95-14.5% | -$0.84— | -$0.88+4.3% | -$0.87+96.0% | -$0.83+95.2% | ||
| -$0.95-14.5% | -$0.84— | -$0.88+4.3% | -$0.87+96.0% | -$0.83+95.2% | ||
| 24.7M+1.4% | 24.4M+117% | 24.5M+29.6% | 24.4M+2,905% | 24.3M+2,906% | ||
| 24.7M+1.4% | 24.4M+117% | 24.5M+29.6% | 24.4M+2,905% | 24.3M+2,906% | ||
| -$23.64M-17.1% | -$20.76M-25.3% | -$21.44M-24.3% | -$21.25M-18.5% | -$20.18M-43.5% | ||
| $912K-51.1% | $1.16M-46.6% | $1.37M-25.7% | $1.56M+131% | $1.86M+187% | ||
| -$121K-194% | $16K+103% | $85K-60.8% | $2K+102% | $129K+228% | ||
| $2K+150% | -$2K— | -$3K+50.0% | -$5K-122% | -$4K-103% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $0— | $0+100% | $0+100% | $0+100% | ||
| -$24.43M-10.2% | -$21.93M-20.1% | -$22.9M-24.9% | -$22.81M-40.9% | -$22.17M-53.0% | ||
| -$23.76M-10.3% | -$21.27M-20.5% | -$22.24M-25.6% | -$22.17M-42.2% | -$21.54M-54.9% | ||
| -$23.76M-10.3% | -$21.27M-20.5% | -$22.24M-25.6% | -$22.17M-42.2% | -$21.54M-54.9% | ||
| -$24.43M-10.2% | -$21.93M-20.1% | -$22.9M-24.9% | -$22.81M-40.9% | -$22.17M-53.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Artiva Biotherapeutics, Inc. profitable?
- Artiva Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $87.1M over the trailing twelve months, a -79.3% net margin.
- What is Artiva Biotherapeutics, Inc.'s earnings per share?
- Artiva Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.54.
- Where does Artiva Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.